Education
About Us
Working with TipRanks
Follow Us
Dynavax Technologies (DVAX)
:DVAX
DVAX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.74 - $14.63
Previous CloseN/A
Volume272.71K
Average Volume (3M)2.57M
Market Cap
$1.31B
Enterprise Value$1.49B
Total Cash (Recent Filing)$30.08M
Total Debt (Recent Filing)$12.85M
Price to Earnings (P/E)61.6
Beta0.26
Next Earnings
May 06, 2025EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.17
Shares Outstanding122,411,680
10 Day Avg. Volume3,514,702
30 Day Avg. Volume2,568,152
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.18
Price to Cash Flow (P/CF)8.10
P/FCF Ratio8.10
Enterprise Value/Market Cap1.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.39
Enterprise Value/Ebitda45.19
Forecast
1Y Price Target
$24.75Price Target Upside129.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
---
Dynavax News
PremiumCompany Announcements
Dynavax Technologies Reports Strong Earnings and Positive Outlook
PremiumCompany Announcements
Dynavax Technologies Reports Strong Growth in 2024---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceHeplisav-B sales grew 39% year over year, with total U.S. market share increasing to approximately 44%.
Market ShareHeplisav is expected to capture at least 60% market share in the adult hepatitis B vaccines market.
ProfitabilityHeplisav-B gross margin was 82%, indicating strong profitability from the product.
Bears Say
Market ConditionsManagement expects ongoing penetration of the unvaccinated adult cohort and observed revaccination practices to sustain substantial market opportunity beyond 2030.
Pipeline DevelopmentThe shingles Phase 2 in adults 50-69 remains on track for updates, but future success depends on key metrics such as one-month-post-second-dose CD4+ T-cells.
Sales PerformanceManagement had anticipated seasonality to reduce Q4 sales by approximately 15%, but the actual decrease was 10%.
---
Ownership Overview
0.50% Insiders
17.78% Mutual Funds
0.22% Other Institutional Investors
56.29% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DVAX FAQ
What was Dynavax Technologies’s price range in the past 12 months?
Dynavax Technologies lowest stock price was $9.74 and its highest was $14.63 in the past 12 months.
What is Dynavax Technologies’s market cap?
Dynavax Technologies’s market cap is $1.31B.
When is Dynavax Technologies’s upcoming earnings report date?
Dynavax Technologies’s upcoming earnings report date is May 06, 2025 which is in 11 days.
How were Dynavax Technologies’s earnings last quarter?
Dynavax Technologies released its earnings results on Feb 20, 2025. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.042 by $0.008.
Is Dynavax Technologies overvalued?
According to Wall Street analysts Dynavax Technologies’s price is currently Undervalued.
Does Dynavax Technologies pay dividends?
Dynavax Technologies does not currently pay dividends.
What is Dynavax Technologies’s EPS estimate?
Dynavax Technologies’s EPS estimate is 0.04.
How many shares outstanding does Dynavax Technologies have?
Dynavax Technologies has 122,411,680 shares outstanding.
What happened to Dynavax Technologies’s price movement after its last earnings report?
Dynavax Technologies reported an EPS of $0.05 in its last earnings report, beating expectations of $0.042. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Dynavax Technologies?
Currently, no hedge funds are holding shares in DVAX
---
Dynavax Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$24.75 (129.81% Upside)
$24.75 (129.81% Upside)
Blogger Sentiment
Neutral
DVAX Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 5.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.0%
Last 30 Days ▲ 8.4%
Last 30 Days ▲ 8.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.41%
12-Months-Change
Fundamentals
Return on Equity
4.48%
Trailing 12-Months
Asset Growth
-1.09%
Trailing 12-Months
Company Description
Dynavax Technologies
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
---
DVAX Company Deck
---
DVAX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call conveyed a positive outlook for Dynavax, highlighted by record revenue growth, market leadership in hepatitis B vaccines, and promising clinical advancements. However, challenges remain in the approval of the hemodialysis vaccine and increasing R&D expenses.Read More>---
DVAX Stock 12 Month Forecast
Average Price Target
$24.75
▲(129.81% Upside)
Technical Analysis
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Evotec AG
―
Best Analysts Covering DVAX
1 Year
1 Year Success Rate
17/28 ratings generated profit
1 Year Average Return
+41.77%
reiterated a buy rating 2 months ago
Copying Matt Phipps's trades and holding each position for 1 Year would result in 60.71% of your transactions generating a profit, with an average return of +41.77% per trade.
---